Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financi... (secular growth occurring in our industry...)

Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results

Date:8/14/2009

secular growth occurring in our industry."

Six Month Results

For the six months ended June 30, 2009, revenues increased approximately 27.5% to $20.7 million compared to the same period in 2008. Gross profit was approximately $14.5 million for the first six months of 2009, representing an increase of 51.9% from the first six months of 2008. Gross margins were 70.2% for the first six months of 2009 compared to 58.9% for the same period in 2008.

Income from operations was $7.8 million for the first six months of 2009, representing an increase of 87.9% over the first six months of 2008. Operating margins were 37.6% for the first six months of 2009 compared to 25.5% for the first six months of 2008. Net income was $5.7 million for the six months ended June 30, 2009, an increase of approximately 58.8% from the same period in 2008. Fully diluted earnings per share were $0.24 compared to $0.15 for the first six months of 2009 and 2008 respectively, based up on 23.7 million and 23.2 million shares.

Balance Sheet and Cash Flow

The Company had a current ratio of 3.2 to 1 and approximately $1.9 million in cash and cash equivalents on June 30, 2009 compared approximately $0.8 million in cash and cash equivalents on December 31, 2008.

Accounts receivable was approximately $15.3 million on June 30, 2009 versus approximately $11.7 million on December 31, 2008. The number of days sales outstanding (i.e. days sales in accounts receivable) increased to 134 for the six months ended June 30, 2009 from 117 for the same period last year due to slower payments of customers during the current economic slowdown.

On June 30, 2009, the Company had stockholders' equity of $29.0 million, with total assets of $36.3 million versus total liabilities of $7.3 million.

For the first six months of 2009, the Company generated approximately $1.2 million in cash fro
'/>"/>

SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:12/15/2009)... Reportlinker.com announces that a new market research ... The Future of Orphan Diseases ... Analysis and Reimbursement ,, ... Summary ,, The author has released ... Diseases Therapeutics - Market Forecasts to 2015, ...

(Date:12/15/2009)... Minn., Dec. 15 The Mosaic Company (NYSE: ... fiscal year 2010 earnings results and financial tables on ... on the New York Stock Exchange. Results will ... ,, The Company will host a conference call with ... the results. The call will begin at 11:00 ...

(Date:12/15/2009)... PHILADELPHIA and LONDON, Dec. 15 ... Thomson Pharma ® has become the first ... trial protocol and outcome information. This highly anticipated ... Pharma customers this month. ,, ... trial intelligence from registries, publications, press releases, conferences, ...

(Date:12/14/2009)... -- Vermillion, Inc. (Pink Sheets: VRML), a ... Wallen, Ph.D. Chief Scientific Officer, Senior Vice ... will be joining its board of directors ... ,, "Bill brings more than 20 years ... biotechnology," said Gail Page, Vermillion Executive Chairperson. ...

[0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement [0] Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call [0] Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials [0] Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors

... Orchid Cellmark Inc.,(Nasdaq: ORCH ), a leading ... its third quarter 2007 financial results on,Thursday, November ... is hosting a,conference call and webcast to discuss ... day. Management will discuss financial results for the ...

... Telik, Inc.,(Nasdaq: TELK ) announced that the ... partial hold on TELCYTA(R) (canfosfamide HCl, TLK286),clinical trials. ... data by,the agency and permits the resumption of ... Alto, CA is a biopharmaceutical company focused on,discovering, ...

... relying on external technologies sourced from start-ups, research ... interact to bring science-driven innovation to market" This ... at the third annual Lux Executive Summit: Connecting ... 15-16, 2007 at the Charles Hotel in Cambridge, ...

Other Biology Technology:Orchid Cellmark to Announce Third Quarter 2007 Financial Results on November 1, 2007 2 FDA Removes Partial Hold on TELCYTA Clinical Development 2 Lux Executive Summit announces 2007 speakers 2

Orchid Cellmark to Announce Third Quarter 2007 Financial Results on November 1, 2007 FDA Removes Partial Hold on TELCYTA Clinical Development Lux Executive Summit announces 2007 speakers

(Date:12/16/2009)... Tom Bowman, an expert in communicating scientific issues to ... developed a series of graphics that translate key figures ... report for public audiences. These new graphics provide non-experts ... make informed decisions about climate change risks and opportunities. ... to clearly and accurately communicate findings in the IPCC ...

(Date:12/16/2009)... 1 iQor, a global provider of business ... InfoWorld 100 Awards Top 100 IT project ... was the first submission for iQor. ,, "We are ... companies," said Vikas Kapoor, president and CEO of iQor. ... allowing us to work faster, smarter and with the ...

(Date:12/16/2009)... REDWOOD CITY, Calif., Dec. 2 ... and authentication solutions, today announced an agreement ... of its DigitalPersona biometric fingerprint technology on ... U.are.U® 4500HD offering allows point-of-sale applications to ... that specific transactions can be linked to ...

Breaking Biology News(10 mins):Bowman creates graphic translation of climate change data 2 iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2 DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2 Injection Reverses Heart Attack Damage 4771 1 Injection Reverses Heart Attack Damage 4771 2 Injection Reverses Heart Attack Damage 4771 3 Injection May Heal Damaged Heart 52560 1 Injection May Heal Damaged Heart 52560 2 International Health Leaders to Share Innovations in Patient Centered Care at 2009 Planetree Annual Conference 52555 1 International Health Leaders to Share Innovations in Patient Centered Care at 2009 Planetree Annual Conference 52555 2 International Health Leaders to Share Innovations in Patient Centered Care at 2009 Planetree Annual Conference 52555 3

[0] Bowman creates graphic translation of climate change data [0] iQor Named to InfoWorld 100 List of Top IT Projects of 2009 [0] DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems

... and gas prices along with the global challenge of ... search for alternative energy sources. A national panel of ... National Meeting in New Orleans to present a comprehensive ... of several significant renewable energy sources. , The ...

... -- Research by two Queens scientists has resulted in an ... such as chemical weapons and pesticides. , Recently completed testing ... method to be greater than 99 per cent effective when ... , When tested in solution, full destruction of all three ...

... research team from the Department of Genetics, Physical Anthropology ... Technology at the Leioa campus of the University of ... de la Ra, has reconstructed the history of the ... using DNA extracted from skeleton remains. , Knowing the ...

Other Biology News:Symposium on energy research highlights future challenges, opportunities 2 Queen's develops safe 'green' decontamination method 2 Ancient DNA: reconstruction of the biological history of Aldaieta necropolis 2 Ancient DNA: reconstruction of the biological history of Aldaieta necropolis 3

Symposium on energy research highlights future challenges, opportunities Queen's develops safe 'green' decontamination method Ancient DNA: reconstruction of the biological history of Aldaieta necropolis

One-step, microplate or cuvet, colorimetric, detection range 0.01 g/dL to 5 g/dL. Procedure: 5 min....

MOUSE ANTI PROTEIN KINASE C BETA 2 Immunogen: Protein kinase C beta 2...

SHEEP ANTI DEHYDROEPIANDROSTERONE...

This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...

Biology Products:

Albumin Colorimetric Assay Kit, QuantiChrom from BioAssay Systems Mouse Anti-Protein Kinase C Beta 2 Monoclonal Antibody, Unconjugated from AbD Serotec Sheep Anti-DEHYDROEPIANDROSTERONE (+DEAHS) Polyclonal Antibody, Unconjugated from AbD Serotec Protein Purification Applications from Promega

Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financi...(secular growth occurring in our industry...)